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Tissue-specific transcription is advantageously investigated by using viral promoters, which are selected for
compact regulatory elements. Mouse mammary tumor virus (MMTV) has adapted to specialized cell types and
targets initially B lymphocytes. We previously showed that, in B-cell lines, glucocorticoid-induced MMTV
transcription requires an ETS family factor, GA-binding protein (GABP), bound in tandem to the MMTV DNA
next to the glucocorticoid receptor (GR). We now report that transforming growth factor  (TGF-) super-
induces this response up to 10-fold through binding of its effectors, Smads, between the GABP-binding motifs.
The basal level was unaffected. The TGF-–glucocorticoid cooperation also depended on GR and GABP
binding, was transferable to another promoter, and occurred both with transiently transfected and with
integrated templates. Smad3 associated in vitro with GR, with GABP (via the MH2 domain), and with
GABP, Smad4 only with GABP. Interactions of Smad3 with GABP (when coexpressed or endogenous to B
cells) were shown by coprecipitation and by mammalian two-hybrid assay. This composite DNA element
integrates three signaling pathways deriving from TGF-, glucocorticoid hormones, and a unique ETS factor,
and may allow MMTV to exploit factors from the milk. It may as well indicate novel possibilities for cellular
regulatory networks.
Transforming growth factor  (TGF-) is a member of a
superfamily of structurally related proteins that regulate cell
differentiation and proliferation in a wide variety of organisms
(reviewed in references 49 and 50). Through serine/threonine
kinase receptors, it activates transcription factors called Smads
along a unique signaling pathway that has been the focus of
intense research efforts in recent years (reviewed in references
4, 51, and 53). Receptor-regulated Smad2 or Smad3 become
phosphorylated and associate with a co-Smad (Smad4). They
activate transcription by binding to DNA elements and/or by
associating with DNA-bound factors. Among these, some were
newly discovered, such as FAST-1 (14) and FAST-2 (43),
whereas others were already known, such as AP-1 (70), Sp1
(54), TFE3 (35), or AML-1 (55). Smad proteins contain highly
conserved domains (see Fig. 6C): an N-terminal, DNA-binding
MH1 and a C-terminal MH2 mediating most protein-protein
interactions. Only rather degenerate common binding se-
quences could be defined by comparing TGF--responsive el-
ements of various genes (18; reference 63 and references
therein). The biological effects of TGF- are extremely varied,
according to the type and environment of the target cell (re-
viewed in references 19 and 49). In the immune system, it
functions as a modulator of differentiation and as an immuno-
suppressor, e.g., in regulating cytokine production by T cells
and immunoglobulin expression by B cells (13, 56). Identifying
novel Smad partners and regulators is crucial for understand-
ing TGF- function.
Mouse mammary tumor virus (MMTV) is a B-type retrovi-
rus that causes carcinomas of the mammary gland in females of
susceptible mouse strains (11) through insertional activation of
cellular int genes (reviewed in reference 66). The major site of
MMTV replication is the mammary gland, under the stimula-
tion of pregnancy-related hormones. MMTV DNA is the pro-
totype gene for studying the genomic effects of glucocorticoids,
i.e., effects that are mediated by binding of the hormone-
activated glucocorticoid receptor (GR) to the glucocorticoid
regulatory element (GRE), upstream of the promoter in the
long terminal repeat (LTR) (9, 10; for a review, see reference
7). The GR contains domains for transactivation, DNA bind-
ing, and hormone binding (see scheme in Fig. 4B) (8, 48).
MMTV has a distinctive tissue specificity of expression and
biological adaptation that make it an unmatched model sys-
tem. For primary infection, MMTV targets B lymphocytes in
the intestine, eliciting a critical immune reaction involving a
viral superantigen (reviewed in reference 47). Lymphocytes are
required for virus transportation to the mammary gland (65),
and B cells are essential for virus propagation in the infected
animal (32). Both B and T cells get infected and are able to
transmit virus (3, 25). We were therefore interested in the
regulation of MMTV expression in B cells. In a recent study we
identified a novel DNA regulatory region, adjacent to the
distal GRE, that contains a tandem of motifs interacting with
the heterodimeric ETS factor GA-binding protein (GABP)
present in mature B-cell lines (5) (see scheme in Fig. 1A). In
these cells the GABP-binding sites are essential for stimulation
by glucocorticoids, and GABP functionally cooperates with the
GR. GABP is composed of a DNA-binding  subunit and a
transactivating  subunit linked to  through ankyrin repeats.
Interactions between  subunits of two neighboring dimers
greatly stabilize the complex on DNA (reviewed in reference
* Corresponding author. Mailing address: Institute of Microbiology,
University of Lausanne, Rue du Bugnon 48, CH-1011 Lausanne, Swit-
zerland. Phone: 41-21-314-4100. Fax: 41-21-314-4095. E-mail: Elena
.Buetti@hospvd.ch.
† Present address: Abbott Científica S.A/ADD Spain, E-28034 Ma-
drid, Spain.
2201
27) (Fig. 1A). Since our study was the first to show cooperation
between the GR and GABP, we were interested in defining
signaling pathways that could act through GAPB and possibly
modify the hormone response.
An involvement of TGF- in the biology of MMTV was
previously described only in mouse mammary tumor cell lines
as an indirect repression of the LTR transcriptional activity
(12). Concerning the site of viral entry, the gut-associated
lymphoid tissue, nothing is known about possible effects of
TGF- on infection by MMTV. In the present study we show
that the LTR element composed of the GRE and two GABP-
binding sites also mediates a transcriptional superinduction by
TGF- of the glucocorticoid effect through the binding of
Smads to DNA located between the GABP sites and protein-
protein interactions involving Smads, GABP, and GR. This
superinduction, observed in B lymphocytes, may play a positive
role in the early phase of viral infection in the gut. On the other
hand, it constitutes a novel combination of sequences and
transcription factors activated by TGF- in a naturally occur-
ring promoter.
MATERIALS AND METHODS
Cells, reagents, and plasmids. M12.4.1 (23), an immunoglobulin G2a-express-
ing BALB/c mouse B-lymphoma cell line representative of mature B cells was
obtained from H. R. MacDonald (Ludwig Institute for Cancer Research, Lau-
sanne, Switzerland) and cultured in Dulbecco modified Eagle medium contain-
ing 5% heat-inactivated fetal calf serum (FCS; both from Gibco-BRL), 50 M
2-mercaptoethanol, 2 mM L-glutamine, and antibiotics. The GR mouse mam-
mary tumor cell line and the COS-7 cell line (24) were maintained in Dulbecco
modified Eagle medium, 10% FCS, and antibiotics. Cultures were kept at 37°C
in a humidified 5% CO2 atmosphere. Dexamethasone (Dex) was from Sigma,
and recombinant human TGF-1 was from Sigma, BioPharmacy Ltd. (Japan), or
R&D Systems. Rabbit polyclonal antibodies against GR (M-20, sc-1004) and
against glutathione S-transferase (GST; Z-5, sc-459) were purchased from Santa
Cruz Biotechnology; rabbit polyclonal antibodies against GABP and GABP
were a generous gift from E. Flory (22). The mouse monoclonal antibodies used
were purchased from Roche (M2 against the Flag peptide and 12CA5 against the
hemagglutinin[HA] peptide), from BD-Transduction Laboratories (against
Smad2/3), and from Santa Cruz Biotechnology (B8 against Smad4). The plas-
mids pCMV5-DPC4-HA (encoding Smad4 with a 3-end HA tag [29]), pCMV/
DPC4(1-514) encoding a truncated form of Smad4 acting as a dominant-negative
mutant, and pCMV5/TR-I (T204D) encoding an activated TGF- receptor
were provided by J. Massague´ (Memorial Sloan-Kettering Cancer Center, New
York, N.Y.). Cytomegalovirus (CMV)-based plasmids expressing the rat GR and
subsets of it—pSTC-TK-GR3-795, pSTC-TK-GR3-556, pSTC-TK-GR407-795,
and pSTC-TK-GR407-556 (41) were provided by S. Rusconi (University of
Fribourg, Fribourg, Switzerland); a plasmid expressing an activated TGF- re-
ceptor R(II-I) (17) was provided by the laboratory of R. Derynck (University of
California, San Francisco). The pGex4-Ti plasmids expressing GST fusions with
Smad4, Smad3, Smad3-MH1, and Smad3-MH2 (36) were from C. H. Heldin
(Ludwig Institute for Cancer Research, Uppsala, Sweden). The plasmid pUC-
In-wt/K1 containing the simian virus 40 (SV40) large-T antigen and a mutated
SV40 origin (21) was from the laboratory of Ellen Fanning via P. Beard (ISREC,
Lausanne, Switzerland). pGL3-Basic vectors (Promega) containing the wild-type
MMTV LTR (GR strain, from positions 1196 to 133 from the RNA start
site), the LTR truncated at position 303, LTRs (full-size or truncated) mutated
in the GABP-binding sites fp1 and/or fp2, LTRs with mutations in the GRE
(LS[193/162] and LS[175/166], carrying an octameric HindIII linker in-
serted between the indicated positions [39]), and the negative control plasmid P
deleted from positions 105 to 133 have been previously described (5). Bac-
terial expression plasmids for GABP or GABP cDNAs fused to GST at their
N termini were made with the pGEX-KG vector (Amersham Biosciences). The
equivalent GST fusions for expression in mammalian cells were constructed in
the pCMV-GST vector received from R. R. Reed, Johns Hopkins University,
Baltimore, Md. (64). The cDNAs of GABP and GABP (22) were subcloned
by PCR starting from the second amino acid to their natural stop codon. Mam-
malian expression plasmids for Smad3-Flag and Smad2-Flag were prepared from
pRK5-vector constructs (received from the laboratory of R. Derynck, University
of California at San Francisco) by subcloning the coding region plus the Flag
epitope and the SV40 origin into the pCI vector (Promega). For Smad3, an
EcoRI/HpaI fragment was ligated into pCI cut with EcoRI and BamHI (filled in
with Klenow enzyme). For Smad2, since it contains an HpaI site, a three-way
ligation of an EcoRI/SalI fragment containing the coding region, a separately
obtained SalI/HpaI fragment containing the Flag epitope and the SV40 se-
quences, and a pCI vector cut with EcoRI and BamHI (filled in with Klenow
enzyme) was performed. Smad3F-N was made from the pCI/Smad3F clone by
digestion with BamHI and PflMI, filling in with T4 polymerase, and self-ligation.
The first AUG in this construct corresponds to amino acid 212, which is roughly
at the start of the MH2 domain. Mutations of the fp1/fp2GRE sites and of the
Smad binding site in the LTR were carried out by the method of splicing-by-
overlap extension of PCR products (33) and verified by sequencing. For con-
structs with the enhancer-less SV40 promoter, a region from positions 209 to
116 was amplified by PCR with linked BamHI and BglII sites. Purified frag-
ments were ligated with BglII-digested pGL3-promoter (Promega) in the pres-
ence of BglII and BamHI to get oriented inserts. For the mammalian two-hybrid
analysis, we used plasmids of the CheckMate system (Promega). The reporter
pG5luc expresses the firefly luciferase under the control of a minimal TATA box
and five GAL4-binding sites. The coding sequences of GABP and of GABP
were each cloned by PCR as EcoRV-XbaI fragments into the pBIND vector in
frame with the yeast GAL4 DNA-binding domain. The coding sequences of
GABP and of Smad3 were each cloned by PCR as EcoRV-XbaI fragments into
the pACT vector in frame with the herpes simplex virus VP16 activation domain.
Cell transfections. M12 cells were transfected by the DEAE-dextran method
as described previously (5). GR mammary tumor cells were transfected by a
different DEAE-dextran method (200 ng of DEAE-dextran/ml for 8 h at 37°C),
followed by a dimethyl sulfoxide shock (10%, 2 min at room temperature).
COS-7 cells were incubated with 5 g of DNA in 2.5-ml/10-cm dish of 500 ng of
DEAE-dextran/ml in phosphate-buffered saline at 37°C for 30 min. After the
addition (12 ml/dish) of medium containing 3% FCS and 0.1 mM chloroquine,
the incubation was continued for 2.5 h at 37°C. The cells were then treated with
10% dimethyl sulfoxide in complete medium for 1.5 min at room temperature,
washed, and incubated overnight. After the medium was changed, the cells were
incubated for another 24 to 30 h. Transfection mixtures also contained Renilla
luciferase expression vectors as internal standards (pRL-SV40 or pRL-TK [Pro-
mega]). A novel control plasmid was constructed (pRL-SV40 enhancer) by
cloning the SV40 promoter from the pGL3-promoter plasmid (digested with
BglII/HindIII) into pRL-null (Promega). Luciferase assays were performed with
the Dual-Luciferase kit (Promega), and measurements of luminescence were
made with a Berthold Lumat luminometer. The results were expressed as the
ratio of the firefly to the Renilla luciferase activities or, in some cases, as the
firefly activity per constant amount of protein (as determined by the BCA assay
[Pierce]) after having verified beforehand the reproducibility of the transfection
conditions (5).
Protein interaction assays. GST fusion proteins were produced and purified as
described previously (36), but bacteria expressing GST-GABP were grown at
16°C for 18 to 24 h after induction due to its instability at higher temperatures.
Whole-cell extracts from COS cells were prepared as described by Liv et al. (44).
GST pull-down assays with bacterial proteins bound to GSH-Sepharose beads
were performed as described by Hittelman et al. (34), with a 4°C incubation and
rotary motion. Isolation of GST-fused proteins made in mammalian cells was
done as described by Tsai and Reed (64). Immunoprecipitation from cell extracts
was done in a lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 8), and
1% NP-40, plus protease and phosphatase inhibitors (28), with 2 g of rabbit
antiserum/ml at 4°C. After the addition of protein A-Sepharose (Sigma) and
rotation at 4°C for several hours, the beads were washed five times with lysis
buffer. Bound proteins were eluted from Sepharose beads, separated by electro-
phoresis in sodium dodecyl sulfate–10% polyacrylamide gels, and transferred to
a nitrocellulose membrane (28). Western immunoblotting and detection with
horseradish peroxidase-coupled goat anti-mouse or anti-rabbit antibodies
(Pierce) and chemiluminescence (SuperSignal West Pico [Pierce]) were per-
formed according to standard protocols (28).
Electrophoretic mobility shift assays (EMSAs). They were performed as de-
scribed previously (5). Double-stranded probes were made by annealing an
oligonucleotide that was 5 end labeled with [32P]ATP and T4 polynucleotide
kinase with its unlabeled complementary strand. Their sequences were as fol-
lows: for the wild-type Smad binding site (Smad B.S.wt), positions 143 to 160
plus three nucleotides on each side (lowercase) with mutated parts of fp1/fp2,
5-cttATGTGAGACAAGTGGTTTatg-3 and 5-catAAACCACTTGTCTCAC
ATaag-3; for the mutant (m, lowercase) Smad binding site, 5-cttATGTGctcac
ctgGGTTTatg-3 and 5-catAAACCcaggtgagCACATaag-3; and for fp1,2, con-
taining both fp1/fp2 binding sites with the Smad box in the middle, positions
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172 to 133, 5-CCAACTCAGGAAACCACTTGTCTCACATCCTTGTTTT
AAG-3 and 5-CTTAAAACAAGGATGTGAGACAAGTGGTTTCCTGAGT
TGG-3. The unlabeled, double-stranded competitor oligonucleotides with a
different sequence were fp2 (175 to 152), 5-ggaCTTAAAACAAGGATGT
GAGAC-3 and 5 GTCTCACATCCTTGTTTTAAGtcc-3. The nucleotides in
lowercase letters were added to avoid an overlap with the GRE. The unrelated,
hepatic nuclear factor 3 binding site of the transthyretin gene (109 to 84) was
5-TGACTAAGTCAATAATCAGAATCAGC-3 and 5-GCTGATTCTGATT
ATTGACTTAGTCA-3.
Biotinylated oligonucleotide precipitation. Wild-type and mutant Smad-bind-
ing site oligonucleotides were synthesized with the addition of biotin to the 5
end of one strand and annealed with the nonmodified complementary strand.
For each binding reaction, 50 pmol of annealed oligonucleotides was coupled to
60 l of streptavidin paramagnetic beads (Promega) in 10 mM HEPES (pH 7.6),
1 mM EDTA, and 2 M NaCl at 25°C for 40 min. The beads were washed four
times in the same buffer by using a magnetic stand. Whole-cell extracts (400 ng)
(44) were precleared with 30 l of streptavidin beads for 3 h on ice and then
incubated with the oligonucleotide-bound beads and 4 g of poly(dI-dC)-
poly(dI-dC) with a final concentration of 10 mM HEPES (pH 7.6), 100 mM
NaCl, 0.1 mM EGTA, 6.6% glycerol, and 0.2% NP-40 for 2 h at 4°C. The beads
were washed four times with 10 mM HEPES–150 mM NaCl–1 mM EDTA–0.1%
NP-40, and bound proteins were analyzed by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis and Western blotting.
Isolation of total RNA and Northern blot analysis were performed by standard
methods (16, 58).
RESULTS
Identification of a TGF-- and glucocorticoid-responsive
DNA sequence in the MMTV LTR. TGF- plays an important
role in cells of the immune system, and we were therefore
interested in examining the possible effects of this cytokine on
MMTV gene expression in the mature B-cell line we are using
as model: the murine M12 B-cell lymphoma. The cells were
transiently transfected with reporter plasmids containing the
firefly luciferase gene under the control of the MMTV LTR (5)
from the mouse strain called GR (the name having no con-
nection to the common abbreviation used for the glucocorti-
coid receptor) in its wild-type form or with various mutations
(Fig. 1A). Transfected M12 cells were treated with TGF- in
absence of serum, with or without the synthetic glucocorticoid,
Dex. The results are shown in Fig. 1B. Whereas the basal level
was slightly reduced, the Dex-induced level of luciferase activ-
ity was increased fivefold by TGF-. The effect appeared as a
superinduction of the glucocorticoid stimulation, as it was
abolished, along with the hormonal induction, in an LTR mu-
tated in the GRE or in both GABP-binding sites (fp1/fp2, Fig.
1B). The superinduction was not restricted to transfected tem-
plates. The level of MMTV RNA transcribed from endoge-
nous proviral copies of M12 cells was also enhanced by TGF-
plus Dex, compared to Dex alone, as shown by Northern blot
analysis of M12 cell RNA (Fig. 1C). We noticed that endoge-
nous transcripts were present at a relatively high basal level,
which could not be increased by Dex. However, only the com-
bination of Dex and TGF- produced an increase (fivefold) of
steady-state endogenous MMTV RNA, suggesting that glu-
cocorticoids are involved in the effect from integrated tem-
plates as well. All forms of endogenous transcripts of B cells
were increased, i.e., the 9-kb full-length, the 3.6-kb env, and the
1.7-kb superantigen-encoding RNAs, as well as a previously
described 2.8-kb RNA (46). A twofold increase of endogenous
MMTV transcripts with Dex plus TGF- was also observed in
primary BALB/c spleen cells cultured for 4 days in the pres-
ence of lipopolysaccharide, a B-cell activator (data not shown).
The cooperative effect of TGF- and Dex observed in B cells
was in striking contrast to the repression observed in the
mouse mammary tumor GR cell line transfected with the same
wild-type LTR reporter. The results with GR cells (Fig. 1D)
showed a drastic reduction of reporter activity in TGF--
treated cells, a finding in agreement with a published report on
endogenous (Mtv-2) transcripts (12). Only the Dex-induced
level could be measured: with this assay, the basal level in
mammary cells, in contrast to B cells, is exceedingly low and
below detection due to negative regulatory factors (71). A
strong negative effect of TGF- was also observed with an LTR
truncated at position 303 or mutated in both GABP-binding
sites. With these two templates, the absolute levels of Dex-
induced activity were lower than with a wild-type LTR due to
the removal of weakly positive elements, as observed previ-
ously (9, 10). These results show that TGF- acts in opposite
ways on the MMTV LTR promoter depending on the cell type
(mature B cells versus mammary tumor cells), suggesting a
tissue specificity of the effect. To start mapping the LTR se-
quences required for the TGF- superinduction in B cells, we
compared the activities of a complete LTR (Fig. 2A) and of an
LTR truncated at position 303 (Fig. 2B). The latter showed
a higher basal level due to the removal of negative regulatory
elements (45) but retained a TGF- induction that was com-
pletely dependent on the GABP-binding sites. With LTRs
carrying only one mutated site (either fp1 or fp2; Fig. 2C), the
residual activities of each mutant showed additivity with re-
spect to glucocorticoid induction, in agreement with our pre-
vious results (5). However, they showed a synergism with re-
spect to the TGF- effect (Fig. 2C), suggesting a requirement
for the occupancy of both GABP-binding sites, presumably by
an 2-2 tetramer (27) for maximal TGF- response.
A minimal construct is active as a dimer with a heterologous
promoter. We next sought to define a minimal effector se-
quence and to assess any contribution by the MMTV pro-
moter. The DNA fragment from positions 209 to 116,
comprising the GRE and the GABP-binding sites with only
short flanking sequences, was cloned in front of the SV40
enhancer-less promoter linked to the firefly luciferase gene,
either as a single copy or as head-to-tail oligomers. The results
of transient assays in M12 cells (Fig. 2D) show that (i) a single
copy was inactive, both in Dex alone and in DexTGF-
stimulation; (ii) a dimer was competent for both effects, to an
extent similar to that of an MMTV-promoter construct; (iii)
three or four copies, but not six, produced a further boost; (iv)
a dimer in reverse orientation with respect to the promoter was
more active than one in a direct orientation. We conclude that
the combination of GRE and GABP-binding sites behaves as
an enhancer sequence similarly to a simple GRE with respect
to glucocorticoid stimulation (67), whereby the superinduction
by TGF- appears as an amplification of the hormone effect.
The pattern of reporter activity of the dimer is reminiscent of
that of the MMTV promoter, which indeed contains two GREs
(10). The essential role of the GABP recognition sequences
was conserved in the heterologous construct, since their mu-
tation abolished the responsiveness of a dimer-containing
plasmid (Fig. 2E), suggesting that the GRE/fp1/fp2 sequence
constitutes an element that mediates the glucocorticoid stim-
ulation and the superimposed TGF- response in B cells.
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A putative Smad-recognition sequence in the MMTV LTR is
involved in the superinduction by TGF- of the glucocorticoid
response in B cells. We noticed that the DNA sequence linking
fp1 and fp2 (position 155/149) resembles some of the pro-
posed binding sites for Smad3/4 (reviewed in references 20 and
51). We mutated this putative AGACA “Smad box” plus three
nucleotides on the 3 side (Fig. 1A) in the context of the
LTR/luciferase reporter plasmid and tested its activity in tran-
siently transfected M12 cells. Two types of results were ob-
tained that depended on the physiological state of the cells at
the time of transfection. On one hand, exponentially growing
cultures showed little reduction of the TGF- effect in pres-
ence of Dex compared to a wild-type LTR (not shown). On the
other hand, cultures that were transfected at a high cell density
showed an impairment of the TGF- superinduction but not of
stimulation by Dex alone (Fig. 3A). This inhibition was not due
to exhaustion of nutrients, since it was not found in cultures
that had been prestarved in absence of serum for 24 h before
FIG. 1. Opposite effects of TGF-1 in a B-lymphoma cell line (B and C) versus a mammary tumor cell line (D). (A) Scheme of the arrangement
of factors binding to the regulatory elements upstream of the MMTV promoter that are relevant for the present study. In the wild-type sequence
(WT), the numbering refers to the transcription initiation site, and fp1 and fp2 denote the DNase I footprints with M12-cell nuclear extracts (5),
with the core sequences for GABP binding in boldface. The putative Smad binding site is also marked. Mutated bases in the different reporter
constructs are in lowercase letters (mGRE, fp1, and fp2 are mutated in all three sites; mSmad B.S. is mutated in the putative Smad binding site
[modified from references 27 and 48]). (B and D) pGL-3 plasmids (B, 3 g; D, 2 g) with various LTRs were transiently transfected into M12 B
cells (B) or GR mouse mammary tumor cells (D) that were kept thereafter in serum-free medium plus 5 ng of TGF-1/ml or the carrier solution
containing bovine serum albumin for 24 h (B) or 46 h (D). The “dex” samples received Dex (50 [B] or 300 [D] nM) for the last 4 h (B) or 8 h
(D) before cell lysis for determination of luciferase activity. The LTRs used were as follows: wild type (Lwt), LTR mutated in the fp1/fp2
GABP-binding sites (Lmut fp1,2), LTR mutated in the GRE (Lmut. GRE [LS193/162] [10]), and LTR 5 truncated at position303 (Lwt-303).
The values for firefly luciferase activity were normalized against the Renilla luciferase activity produced by cotransfected plasmids (50 ng of
pRL-SV40 enhancer [B] or 200 ng of pRL-SV40 [D]). Error bars denote the standard deviations in duplicate samples. The experiment in panel
D was performed twice; the experiment in panel B was performed many times. (C) Cooperative effect of TGF-1 and Dex on the endogenous
MMTV RNA levels of M12 cells. Northern blot analysis of total RNA from M12 cells treated with TGF-1 (5 ng/ml) or bovine serum albumin
buffer for 24 h in serum-free medium in the presence or absence of 50 nM Dex for the last 4 h before RNA extraction. Total RNA was separated
in a 1% agarose gel containing formaldehyde and blotted onto a nylon membrane, which was hybridized with a 32P-labeled probe of the MMTV
env region (upper panel) and then with a probe of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA as a loading control (lower
panel). RNA samples are in duplicate. On the right, the sizes in kilobases of the viral mRNAs are given (see the text). The total intensity of the
MMTV bands relative to the GAPDH control was quantified and plotted (relative MMTV RNA; values  the standard deviation are indicated).
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transfection (not shown). This difference may suggest the ex-
istence of redundant signaling pathways for TGF- (50); alter-
natively, the mutation may be partially compensated for in
actively growing cells by protein-protein contacts of Smads
with GR and GABP (see below). To see whether one could
affect the process, we overexpressed either Smad4 or Smad3
(Fig. 3B) with the wild-type LTR reporter construct. An in-
crease (	2-fold) of the TGF- superinduction was detected in
several instances, but not always, reflecting a difficulty often
encountered in this type of experiments with cells endowed
with endogenous levels of factors (Fig. 3E shows a Western
immunoblot for Smad3 and Smad4 of TGF-Dex-treated
M12 cell extracts). The role of Smad proteins in the TGF-
superinduction was confirmed when dominant-negative mu-
tants of Smads were used (Fig. 3C). Overexpression of trun-
cated forms of Smads lacking essential domains for mutual
interaction (Smad4C [68]) or for nuclear translocation
(Smad3N [69]) reduced the extent of TGF- superinduction
(Fig. 3C). Smad4C also inhibited the Dex response by an
unidentified mechanism that might involve protein-protein in-
teractions (see below) and will require further analysis. The
peculiar position of the Smad recognition sequence, which is
intercalated between the GABP-binding sites next to the GRE
suggested that it may depend for its function on their occu-
pancy by the cognate factors. The DNA-binding ability of
Smads is generally low, and it relies in many instances on
cooperation with other DNA-binding factors. We therefore
tested the ability of overexpressed Smad3 to further increase
the TGF- superinduction by using LTR templates mutated in
the GABP-binding sites, or in the GRE, or in all sites. As
shown in Fig. 3D, mutations in either the GRE or the GABP
sites still allowed some TGF- effect, whereas an LTR mutated
in both the GABP and the GRE sites was unable to respond,
despite the presence of the intact Smad binding site. This result
suggests a participation of GABP and GR to the enhancement.
We next sought to define more precisely the role of the GR in
the TGF- response. The partial agonist RU486, which can
bind to the receptor and induce its nuclear translocation but
FIG. 2. The GABP-binding sites are required, together with the
GRE, for the TGF- superinduction of the MMTV promoter (A, B,
and C) and of the SV40 promoter (D and E). Transient transfection
and treatment of M12 cells were as described in the legend to Fig. 1B.
(A to C) pGL3-basic containing the following LTRs: wild type (wt
LTR or Lwt); LTR mutated in fp1/fp2 (LTR mut. fp1/fp2 [see Fig.
1A]); LTR 5 truncated at 303, wild type (-303 wt), or LTR mutated
in fp1/fp2 (-303 mut. fp1/fp2); LTR mutated only in fp1 (Lmut fp1) or
in fp2 (Lmut fp2); a promoter-negative LTR deleted from positions
105 to 133 (P1), as a negative control. (D and E) pGL3-(SV40)-
promoter containing the indicated number of head-to-tail boxes (nb.
box) with the wild-type sequence from positions 116 to 209 (2i 

two in inverted orientation) (D) or none (), or else two boxes, either
wild type (wt) or mutated in the GRE (mutGRE 
 LS175/166
[10]), in fp1/fp2 (mut fp1,2), or in both GRE and fp1/fp2 (mutGRE 
fp1,2) (E). The negative control was as in panel C. Cotransfected
internal standards (50 ng) were pRL-SV40 in panels A and B and
pRL-SV40 enhancer in panels C, D, and E. Error bars indicate the
standard deviations. Experiments were repeated at least twice.
FIG. 3. Smad proteins and a putative Smad-binding site in the
MMTV LTR between fp1 and fp2 play a role in TGF- superinduc-
tion. Transient transfection and treatment of M12 cells were as de-
scribed for Fig. 1B. The internal control was pRL-SV40 enhancer (50
ng in panels A, B, and D and 25 ng in panel C). (A) pGL3-Basic (3 g)
with a wild-type LTR (LTR wt) or an LTR with an 8-bp mutation
between fp1 and fp2 (LTR mut. Smad B.S. [see Fig. 1A]) were trans-
fected into M12 cells grown to high density (see the text). The result is
representative of two independent experiments with duplicate sam-
ples. (B) Three micrograms of pGL3-basic/wt-LTR was cotransfected
with 3 g of either empty pCI vector (mock), pCMV5-DPC4-HA
expressing the Smad4 protein or pCI-Smad3F. (C) One hundred nano-
grams of pGL3-basic/wt-LTR were cotransfected with 8 g of either
empty pCI vector (mock), pCMV/DPC4(1-514) (Sm4 C), or pCI-
Smad3F N (Sm3 N). (D) pGL3-basic (3 g) with a wild-type LTR
(wt), or an LTR mutated in fp1 and fp2 (mut fp1,2; see Fig. 1A), or in
GRE (mut GRE 
 LS 175/166 [10]), or in both GABP and GR
binding sites (mut fp1,2/GRE) was cotransfected with 6 g of either
pCI () or pCI-Smad3F (). Error bars indicate the standard devia-
tions. (E) Western immunoblot of a whole-cell lysate from M12 cells
treated with TGF- plus Dex. Replicated slots were blotted and as-
sayed with antibodies to Smad2/3 (lane 1) or Smad4 (lane 2). The
position of molecular size markers is indicated on the left in kilodal-
tons.
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does not efficiently activate transcription, did not cooperate
with TGF- (data not shown), suggesting a requirement for the
transactivation function(s) of the receptor. We showed previ-
ously that in M12 cells the Dex induction due to endogenous
receptor could be significantly improved by overexpressing a
full-length GR (amino acids 3 to 795) exogenously (5) (Fig.
4A). Figure 4A also shows that addition of TGF- superin-
duced this (already increased) level by fourfold. To start iden-
tifying the domains of the receptor participating in the TGF-
response, we introduced mutant GRs lacking various domains
(Fig. 4B) in a cotransfection assay, and compared the super-
induction factors with that of the full-length protein (Fig. 4A).
As expected, the results in the absence of TGF- showed
variable absolute levels of activity depending on the forms of
truncated GR. Their respective functions have been elucidated
previously (41) and were verified in the present context, indi-
cating that the overexpression levels were sufficient to over-
come the action of endogenous GR. The constitutively active
mutant GR(3-556) was still stimulated twofold in the presence
of TGF-, whereas GR(407-795), a dominant-negative mutant
with respect to Dex induction, was unable to cooperate with
TGF-. Surprisingly, GR(407-556), including only the DNA-
binding and a weak transactivation function (52) mediated a
threefold increase by TGF-. These data suggest that the GR
C-terminal domain exerts an inhibitory effect on the TGF-
response, whereas a minimal DNA-binding domain of GR is
able to mediate a TGF- induction.
Smad3 and Smad4 bind to an AGACA box in the LTR at
position 155. To verify the role of the putative Smad box
defined above by mutation, we used it as a probe for EMSAs
with bacterially produced GST-Smads (see scheme in Fig. 6C).
Full-length Smad4 and the DNA-binding moiety of Smad3
(Smad3MH2 [29]) formed retarded complexes (Fig. 5A and
B), whereas GST alone did not (Fig. 5A, lane 1) nor, as ex-
pected, did a Smad3 lacking the MH1 domain (Smad3MH1;
Fig. 5A, lane 3). The presence of two retarded complexes is
likely due to homodimer formation (38). Because Smads can
form heterodimers, we tested the combination of GST-Smad4
with the GST-tagged subsets of Smad3 in EMSAs by using the
GST protein as a control (Fig. 5A). We found no evidence for
higher-order complexes but rather an inhibition of Smad4
binding to the probe in the presence of Smad3-MH2 (lane 6
versus lane 4). The complexes of Smad4 and of Smad3MH2
were competed for by unlabeled homologous oligonucleotides
(Fig. 5B, lanes 2 and 6) but not by a heterologous one (lanes 3
and 7). No complexes were detected (Fig. 5A, lane 7; Fig. 5B,
lanes 4 and 8) with a probe that included the same base mu-
tations (Fig. 1A) that abolished the TGF- response in the
luciferase assay (Fig. 3A). To demonstrate the binding of full-
length Smad3 to the MMTV AGACA box, we used a DNA
precipitation assay. A biotinylated double-stranded oligonucle-
otide containing the wild-type Smad-binding site, but not one
containing the mutation in the relevant bases, was able to
precipitate Flag-tagged Smad3 from transfected COS cell ly-
sates (Fig. 5C). The coexpression of an activated TGF- re-
ceptor improved the binding only slightly. We conclude that
Smad proteins, purified from bacteria or present in a mamma-
lian cell lysate, are able to bind the MMTV LTR sequence
between the GABP-binding sites shown in Fig. 1A.
In vitro association between Smads 3/4 and GABP and be-
tween Smad3 and GR. GST fusion proteins with GABP or
GABP were produced in bacteria (Fig. 6B) and incubated
with extracts of COS cells overexpressing epitope-tagged
Smads in GST pull-down assays (Fig. 6A). HA-Smad4 inter-
acted with GST-GABP (Fig. 6A, lane 1) but not with GABP
or with GST alone (lanes 2 and 3). Flag-Smad3 interacted with
GABP (lanes 7 and 15) and GABP (lanes 6 and 14) but not
with GST (lane 5). Flag-Smad2 (another receptor-regulated
Smad) interacted more weakly than Smad3 with GABP (lane
13) and even less with GABP (lane 12). In some experiments,
Smad3 also bound less well to  than to  (lane 7 versus lane
6 and data not shown). Whether the interaction is direct or
requires an intermediate protein from the cell lysate will have
to be determined. An N-terminally truncated Smad3 (Sm3N)
containing essentially the MH2 domain (see scheme in Fig.
6C) was also able to interact with GST-GABP (Fig. 6A, lane
11). GST pull-down assays were also performed by using bac-
terially produced GST-Smad3 or truncated forms of it (lacking
either the MH1 or the MH2 domains; Fig. 6D, lanes 5 to 7)
linked to GSH-beads and incubated with extracts of COS cells
overexpressing untagged GR (either full-length or truncated at
the C terminus; see scheme in Fig. 4B). GR was subsequently
detected on a Western immunoblot with an antibody recogniz-
ing its N-terminal portion. Full-length GR was pulled down by
GST-Smad3 (Fig. 6D, lane 2), pulled down more weakly by
Smad3-MH1 (lane 3) and Smad3-MH2 (lane 4), and not
pulled down by GST alone (lane 1). The GR subfragment
FIG. 4. Differential contributions of GR domains to the TGF-
superinduction. Transient transfection and treatment of M12 cells
were as described for Fig. 1B. (A) Cotransfection of 3 g of pCI vector
(mock) or of pSTC-TK encoding various parts of the rat GR (see
scheme in panel B) with 3 g of pGL3-basic/wt LTR. Normalization
was done with the protein content, and error bars denote the standard
deviations. Note the difference in scale between the left and right
portions of panel A. (B) Scheme of the GR and its segments used in
panel A. Numbers to the right indicate amino acids. Positions 3 to 795
is the full-length GR. A to F above the line denote conventional
divisions of the GR. Below the line are functional domains for trans-
activation (AF-1 and AF-2), DNA binding (DBD), and ligand binding
(LBD). BSA, bovine serum albumin.
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GR(3-556) also reacted with GST-Smad3 (lane5) and weakly
with Smad3-MH2 (lane 7) but not with Smad3-MH1 (lane
6). In contrast, no interactions were detected between any of
the GST-Smads (3 or 4) constructs mentioned above and an
epitope-tagged GR fragment containing essentially the DNA-
binding domain (positions 407 to 556 [see scheme in Fig. 4B;
data not shown]).
In vivo association between Smad 3 and GABP. To assess
whether interactions observed by in vitro GST pull-down as-
says also occurred intracellularly, we applied various experi-
mental approaches to the instance of Smad3-GABP. (i) We
used a mammalian CMV-GST vector to coexpress GST-fused
GABP or GABP with tagged Smad3 in the same cells,
namely, COS-7 (Fig. 7A) or M12 (Fig. 7B). In both cell types,
isolation of the GST-carrying proteins on glutathione beads
caused the copurification of Smad3: with GABP (Fig. 7A and
B, lane 1) and with GABP (Fig. 7A, lane 3, and 7B, lane 2).
The C-terminal MH2 portion of Smad3 (N) was also found in
association with GABP in COS cells, similar to the in vitro
observation (Fig. 7A, lane 2). As a control, no Smad3 or
Smad3N was pulled down by the coexpressed GST protein
alone (Fig. 7A, lanes 4 and 5, and B, lane 3). (ii) Anti-GABP
immunoprecipitates of endogenous GABP from TGF--
treated M12 cells contained endogenous Smad3 (Fig. 7C, lane
1), which was not immunoprecipitated by a control antiserum
(Fig. 7C, lane 2). (iii) Finally, intracellular interactions be-
tween Smad3 and GABP were assayed by using a mammalian
two-hybrid system in COS cells, which lack endogenous GABP
(Fig. 7D). Luciferase activity from a promoter preceded by five
GAL-binding sites was measured in presence of cotransfected
GABP fused to the GAL4 DNA-binding domain and of
Smad3 fused to the VP16 activation domain. An enhancement
of 	3-fold was observed, compared to VP16 alone (Fig. 7D,
lane 4 versus lane 3). GABP fused to the GAL4 DNA-bind-
ing domain displayed, as expected, an intrinsic transactivation
(Fig. 7D, lane 5), which was increased threefold by the coex-
pression of Smad3-VP16 (Fig. 7D, lane 6 versus lane 5). These
results suggest that Smad3 associates with each of the GABP
proteins in the nucleus of transfected COS cells, albeit not as
strongly as GABP with GABP, which were used as positive
control (Fig. 7D, compare lane 7 to lane 3).
DISCUSSION
For a specific transcriptional TGF- response, it is essential
that Smads interact with DNA-binding partners. Of particular
interest are combinations with signal-activated factors, leading
to convergence of pathways (reviewed in references 4 and 51).
We identified here a novel configuration of Smad partners,
cooperating on the natural MMTV promoter in a cell type-
restricted manner. TGF- exerts here a positive modulation
(up to 10-fold) on the activated GR, itself requiring an ETS
family factor, GABP, for transcriptional stimulation in B cells
(5). The inhibition observed in mammary cells confirms previ-
ous observations (12) and underscores the differential modes
of action of TGF- in epithelial versus B cells (50), as well as
the tissue specificity of the MMTV LTR promoter. Impor-
tantly, the TGF-–GR cooperation was also found with an
FIG. 5. Direct binding of Smad3 and Smad4 to the MMTV LTR sequence 160/143 containing an AGACA (Smad) box. (A) EMSA with
E. coli-expressed GST-Smads or GST control alone (lane 1) incubated with 32P-labeled probes encompassing the putative Smad box (without
fp1/fp2 [Smad B.S. wt]) or a mutated one (mt, lane 7; see Fig. 1A). ns, nonspecific. (B) EMSA with E.coli-expressed GST-Smads and the wild-type
Smad box probe (wt, lanes 1 to 3 and 5 to 7) or the mutated box (m, lanes 4 and 8). Unlabeled, double-stranded oligonucleotides were added in
	300-fold excess over the probe (lanes 2 and 6). Their sequences were as follows: wild type (wt) or an unrelated (u) hepatic nuclear factor 3 binding
site. (C) DNA precipitation assay. Lysates of COS cells expressing Flag-Smad3 with (lanes 2 to 4) or without (lane 1) an activated TGF- receptor
(T204D) were incubated with biotinylated, double-stranded Smad-binding site probes, either wild type (wt, lanes 1 to 3) or mutated (mut, lane 4),
and precipitated with streptavidin magnetic beads. DNA-bound precipitates (DP; upper panels) or aliquots of input lysates (lower panels) were
subjected to immunoblot analysis with an anti-Flag antibody. Lanes 1 and 2 and lanes 3 and 4 are from two independent experiments.
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integrated MMTV template, suggesting that cellular genes
may respond similarly if endowed with the appropriate DNA
elements. MMTV displays an extreme compression of regula-
tory sequences, with a Smad box tightly inserted between two
GABP-binding sites, themselves adjacent to a GRE (see
scheme in Fig. 1A). We showed in vitro binding of Smads,
produced in bacteria or mammalian cells, to the MMTV Smad
box (Fig. 5), the mutation of which reduced or abolished the
TGF- superinduction in the B-cell reporter assay (Fig. 3A). A
dimer of the fragment, including the GR-, GABP-, and Smad-
FIG. 6. Association of Smads with GABP and GR in vitro. (A)
GST pull-down assays were performed as described in Materials and
Methods. GST-GABP (), GST-GABP (), or GST vector alone (V)
bound to glutathione-Sepharose beads were mixed with whole-cell
lysates (WCE) of transfected COS cells expressing HA-Smad4 (lanes 1
to 3), Flag-Smad2 (lanes 12 and 13), or Flag-Smad3 (full-length in lanes
5 to 7 and lanes 14 and 15 or N terminally deleted in lane 11). The eluted
complexes were analyzed by Western immunoblot with antibodies di-
rected to the respective epitope tags. Lanes without added beads ()
contain ca. 5% of the whole-cell lysate inputs as a control. (B) Pon-
ceau-S-stained membrane corresponding to lanes 5 to 7 of panel A
showing the GST proteins. Numbers on the left identify the molecular
mass markers on the same gel. (C) Scheme of the Smad3 protein and
its domains. Horizontal brackets below denote the fractions of the
protein present in the mutants used. (D) Beads carrying GST fusions
with the indicated parts of Smad3 (see scheme in panel C) or the GST
vector (V) were mixed with whole-cell lysates (WCE) of transfected
COS cells expressing full-length GR (GRwt) or an N-terminal frag-
ment (GR 3-556; see scheme Fig. 4C). The eluted complexes were
analyzed by Western immunoblot with antibodies against GR that
recognize its N-terminal domain. The diffuse spot in lane 6 is due to
nonspecific sticking of the secondary antibody to GST-Smad3MH1
(see lane 6). Lane 8 shows the input lysate (	5%). Lanes 5 to 7,
Ponceau-S-stained membrane corresponding to lanes 5 to 7; lane M,
molecular size markers (numbers on the right in kilodaltons).
FIG. 7. Intracellular interactions of Smads with GABP in COS cells
(A and D) and M12 B cells (B and C). (A) COS cells were cotrans-
fected with CMV-based plasmids expressing Flag-tagged Smad3 (full
length or N terminally deleted, as depicted in Fig. 6C), a constitutively
active TGF- receptor, and a mammalian CMV-GST vector encoding
GST-fused GABP or GABP or GST alone (vector, lanes marked
V). Whole-cell lysates were incubated with glutathione-Sepharose beads,
and bound proteins were analyzed by Western immunoblotting with an
anti-Flag antiserum. (B) M12 cells were cotransfected with CMV-
based plasmids expressing Flag-tagged Smad3, GST-GABP, GST-
GABP, or vector (V); a constitutively active TGF- receptor; and a
plasmid encoding the SV40 large-T antigen. The subsequent steps
were as in panel A. (C) Interaction between endogenous factors of
M12 cells treated with TGF-1 (5 ng/ml) for 30 min after a 15-h
incubation in serum-free medium. GABP was immunoprecipitated
from one-half of the soluble cell extract with rabbit polyclonal anti-
bodies against GABP and GABP (lane 1). Control rabbit serum
against an unrelated antigen was added to the other half (lane 2). After
addition of protein A-Sepharose, bound proteins were analyzed by
Western immunoblot with a monoclonal anti-Smad3 antibody. Lanes 3
and 4 contain aliquots of the cell lysate blotted with anti-Smad3 (lane
3) or anti-GABP (lane 4, from a different gel). (D) Mammalian
two-hybrid assay in COS cells transfected with a luciferase reporter
plasmid driven by a promoter with five GAL-binding sites, in combi-
nation with the plasmids indicated by the “” signs. The suffix “Bind”
denotes constructs with the GAL4-DNA-binding domain; “Act” de-
notes constructs with the VP16 activation domain. Control plasmids
were the respective vectors (V, first two lines). Statistically significant
differences were observed between columns 3 and 4 (P value 
0.0001), columns 5 and 6 (P 
 0.0009), and columns 3 and 7 (P 
0.0001). For more details, see Results.
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binding sites was functional in front of a heterologous pro-
moter, showing the same dependence on the GRE and GABP
sites as in MMTV (Fig. 2D and E). Overexpression of Smads
could moderately increase the TGF- superinduction and par-
tially compensate for the absence of one (but not both) neigh-
boring sites, suggesting interactions between Smads and GR/
GABP (Fig. 3). These interactions were verified for the GR by
cotransfection in the reporter assay (Fig. 4) and for both
GABP and GR by GST pull-down assays in vitro (Fig. 6).
Moreover, we could show an intracellular association between
Smad3 and GABP: (i) in COS cells, by cotransfection of GST-
GABP and Smad3 and by a mammalian two-hybrid assay, and
(ii) in M12 cells (where the functional synergy takes place), by
GST pull-down of transfected factors and by coimmunopre-
cipitation of the endogenous factors (Fig. 7). The fact that the
interaction was specific but not quantitative might point to a
role for the specific DNA sequences as a stabilizing element.
This question will be studied in further investigations.
Due to their low DNA-binding sequence specificity, Smad
boxes frequently function only as multimers (60), and Smads
often act in concert with other transcription factors bound
nearby to the DNA (reviewed in reference 63). Of the ETS
factor family, only Ets1 was shown, in a recent study, to par-
ticipate in the TGF- response of a gene in breast cancer cells,
along with Sp1 (42). The situation of the MMTV LTR in B
cells differs from many described previously in that TGF-
does not affect the basal transcription level (itself not requiring
GABP) but acts to amplify the glucocorticoid-mediated stim-
ulation (which requires GABP, in addition to GR [5]). The
peculiarly dense arrangement of DNA elements in MMTV
may raise the question of steric hindrance. In vitro, the MH1
domain of Smad3 binds to a single Smad box through a 
hairpin embedded in the DNA major groove, allowing simul-
taneous binding of factors close by on the DNA (59). Since the
structure of GABP bound to a direct repeat of ETS sites is
known (6), it will be interesting to model the situation on the
inverted repeat of MMTV DNA. An interaction between fac-
tors binding so closely to each other was first suggested by the
strong dependence of the TGF- superinduction on the integ-
rity of the neighboring sites and by the synergistic contribution
of each GABP site (Fig. 2C). The results of GST pull-down
assays revealed GABP as a novel partner for Smads (Fig. 6).
We found an interaction of GABP with Smad4 and with
Smad3 (in its MH2 domain) and of GABP with Smad3 but
not Smad4. Since the GABP subunits contain a number of
characterized domains (6), it will be of interest to analyze the
contacts in more detail.
Concerning the interactions between Smad3 and GR, the
indications from GST pull-down assays (Fig. 6D) are appar-
ently at variance with those of transient-transfection assays
(Fig. 4A), but the parameters involved are quite different. A
GR fragment from amino acids 407 to 556 (containing essen-
tially the DNA-binding domain; Fig. 4B) was able to cooperate
in the TGF- superinduction; however, it did not show any in
vitro interactions with Smads (data not shown). Interestingly,
we observed an in vitro interaction between GR(407-556) and
GABP (E. Buetti, unpublished observations). When the DNA-
binding domain was extended to the C terminus [in GR(407-
795)], it suppressed the TGF- superinduction, suggesting an
inhibitory function for this domain. This was not the case for a
GR extended on the N-terminal side [i.e., GR(3-556); Fig. 4A].
These results point to distinct interactions of GR domains with
DNA-bound Smads. In GST pull-down assays (Fig. 6D), full-
size GR was able to bind full-size GST-Smad3 and also, albeit
less well, Smad3 with MH1 or MH2 (Fig. 6C) deleted. How-
ever, GR(3-556) could only bind Smad3-MH2 and not Smad3-
MH1, suggesting contacts between the GR-N terminus and
the MH1linker region of Smad3 and, by default, between the
GR-C terminus and the MH2linker region. Further studies
will be performed to better define the interacting domains.
Of the steroid receptor family, the activated vitamin D re-
ceptor was shown to be potentiated by Smad3 through the
MH1 domain (70). Whether Smad boxes on the same DNA are
also required (62) is a matter of debate. Contrasting results
have been reported also on the androgen receptor, either re-
pressed (30) or enhanced (37) by Smad3 in different cells.
Conversely, the activated androgen receptor repressed the
TGF- induction of a gene in prostate cancer cells by prevent-
ing Smad3 binding to DNA (15). The GR was shown previ-
ously to interact with Smad3 and to inhibit the TGF- re-
sponse of the plasminogen activator inhibitor-1 promoter.
Interestingly, the repression was not reciprocal (61). In con-
trast to the above examples, the region of the MMTV pro-
moter analyzed here contains a combination of regulatory se-
quences that possibly evolved to accommodate viral expression
in cell types equipped with particular sets of signaling pathways
and transcription factors. From the standpoint of the virus, a
transcriptional upregulation of the MMTV promoter by
TGF- in B cells may play a role during the primary infection
process, which is remarkably inefficient (31). TGF- is present
at a high concentration in maternal milk and is locally pro-
duced in the postnatal small intestine (26, 57); TGF-, se-
creted by intestinal epithelial cells (26), plays a major role in
the homeostasis of B cells in the Peyer’s patches and is critical
for immunoglobulin A production (13). Glucocorticoids are
present in milk (1) and can be taken up by suckling mice, where
they remain biologically active (2); they were shown to vari-
ously affect B-cell populations (40). Although the biological
implications of TGF- superinduction for the virus life cycle
are still speculative, the identification of GABP and GR as
functional partners of TGF- signaling in B lymphocytes opens
the way to further investigations of protein-protein and pro-
tein-DNA interactions taking place on this composite en-
hancer sequence and of the connected pathways. The results
may reveal novel aspects of regulatory networks involving
TGF-, and further studies will determine whether they oper-
ate in the regulation of cellular genes as well.
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